Saturday 17 October 2026
Export FLNA’s income statement to Excel — free account
Cassava Sciences, Inc.
FLNA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 80.4% and free cash flow grew 21.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.71
0.05
−6.58%
Follow FLNA
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 3.57 | 3.10 | 0.76 | 0.84 | 1.63 | 6.78 | 13.84 | 12.32 | 2.23 | 1.15 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 21.00 | 9.31 | 12.80 | 7.20 | 12.68 | 146.16 | 62.49 | 38.53 | 42.20 | 4.98 | |||||
| People | |||||||||||||||
| People | Employees | 9 | 9 | 9 | 9 | 11 | 24 | 26 | 29 | 30 | 17 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (2.31) | (1.82) | (0.61) | (0.27) | (0.24) | (0.82) | (1.90) | (2.32) | (0.53) | (1.88) | |||||
| Cash flow | (1.88) | (1.26) | (0.45) | (0.14) | (0.21) | (0.77) | (1.93) | (1.96) | (2.52) | (0.67) | |||||
| Capex | (0.01) | 0.00 | 0.00 | 0.00 | 0.01 | (0.56) | (0.07) | (0.01) | 0.00 | (0.01) | |||||
| Free cash flow | (1.89) | (1.26) | (0.45) | (0.15) | (0.19) | (1.33) | (2.00) | (1.97) | (2.53) | (0.68) | |||||
| Book value | 2.86 | 1.48 | 1.84 | 1.27 | 3.53 | 6.44 | 5.66 | 3.28 | 3.15 | 1.54 | |||||
| Shares, m | 7 | 7 | 11 | 17 | 26 | 39 | 40 | 42 | 46 | 48 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (12) | (8) | (5) | (3) | (5) | (30) | (78) | (82) | (117) | (32) | ||||
| Capex | 0 | — | — | 0 | 0 | (22) | (3) | 0 | 0 | (1) | |||||
| Free cash flow | (12) | (8) | (5) | (3) | (5) | (52) | (80) | (82) | (117) | (33) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 18 | 10 | 20 | 22 | 92 | 232 | 204 | 115 | 125 | 54 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | (19) | (10) | (20) | (23) | (94) | (233) | (201) | (121) | (129) | (96) | |||||
| Shareholders’ equity | 19 | 10 | 20 | 22 | 92 | 254 | 228 | 137 | 146 | 74 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (57.99) | (79.06) | (42.34) | (21.23) | (10.76) | (17.94) | (30.40) | (50.31) | (15.75) | (65.95) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (100.31) | (188.56) | (405.48) | (516.08) | 0.00 | |||||
| ROE | (61.87) | (84.07) | (44.72) | (22.20) | (11.08) | (18.71) | (31.67) | (53.27) | (17.19) | (82.66) | |||||
Negative figures in brackets.
Fiscal years to Dec 2013 · latest quarter Dec 2013
Charts ten years each
Cassava Sciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LBPS 4D pharma PLC Sponsored ADR | $37.2M | — (loss-making) | — | +41.64% (above 0%: growing) | n/m | −16,367.69% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| EXOZ eXoZymes Inc. | $37.1M | — (loss-making) | — | — | n/m | −3.25% (below 0%: shrinking) | — | 0.00% | Compare |
| FLNA Cassava Sciences, Inc. | $36.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | |
| LITS Lite Strategy, Inc. | $36.3M | — (loss-making) | — (loss-making) | +647.96% (above 0%: growing) | n/m | +179.28% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDSA Edesa Biotech, Inc. | $36.1M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NNVC NanoViricides, Inc. | $35.0M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $35.5M | — | — | −28.98% | — | −15.07% | 0.00% | 0.00% |
Cassava Sciences, Inc. (FLNA) key facts
- Cassava Sciences, Inc. (FLNA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, FLNA traded at $0.71, a market capitalization of $36.8 million.
- Return on equity was −82.7% and debt-to-equity 0.00.